Cano Health, Inc.
CANO · NYSE
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 0.04 | -0.00 |
| FCF Yield | -34.74% | -2.95% | -7.54% | -10.84% |
| EV / EBITDA | -3.06 | -8.82 | -173.16 | -2,230.42 |
| Quality | ||||
| ROIC | -47.23% | -16.18% | -0.88% | -1.51% |
| Gross Margin | 1.98% | -7.78% | 10.40% | 15.73% |
| Cash Conversion Ratio | 0.08 | 0.06 | 0.49 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 28.50% | 35.47% | 43.77% | 57.86% |
| Free Cash Flow Growth | -114.90% | 37.26% | 52.44% | -252.40% |
| Safety | ||||
| Net Debt / EBITDA | -2.76 | -5.48 | -124.52 | -1,419.35 |
| Interest Coverage | -15.75 | -9.19 | -1.43 | -1.35 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5.85 | -1.02 | 11.80 | 14.33 |